Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Feb 2013 12:47 PM
RNS
Director/PDMR Shareholding
21 Feb 2013 09:49 AM
RNS
Director/PDMR Shareholding
07 Feb 2013 07:00 AM
RNS
Venn Life Sciences expands into Russia
09 Jan 2013 07:00 AM
RNS
Notification of Major Interest in Shares
07 Jan 2013 07:00 AM
RNS
Contract Win
14 Dec 2012 07:00 AM
RNS
Admission to trading on AIM
12 Dec 2012 07:00 AM
RNS
Notification of Major Interest in Shares
12 Dec 2012 07:00 AM
RNS
Notification of Major Interest in Shares
12 Dec 2012 07:00 AM
RNS
Trading Update
13 Nov 2012 07:00 AM
RNS
Notification of Major Interest in Shares
22 Oct 2012 07:00 AM
RNS
Contract Win
05 Oct 2012 07:00 AM
RNS
Notification of Major Interest in Shares
24 Sep 2012 07:00 AM
RNS
Half Yearly Report
06 Aug 2012 07:00 AM
RNS
Notification of Major Interest in Shares
17 Jul 2012 07:00 AM
RNS
Notification of Major Interest in Shares
27 Jun 2012 10:03 AM
RNS
Notification of Major Interest in Shares
22 Jun 2012 11:45 AM
RNS
Notification of Major Interest in Shares
07 Jun 2012 09:23 AM
RNS
Notification of Major Interest in Shares
25 May 2012 07:00 AM
RNS
Notification of Major Interest in Shares
24 May 2012 07:00 AM
RNS
Notification of Major Interest in Shares
16 May 2012 07:00 AM
RNS
Notification of Major Interest in Shares
10 May 2012 04:42 PM
RNS
Notification of Major Interest in Shares
10 May 2012 02:00 PM
RNS
Contract Win
10 May 2012 07:00 AM
RNS
Notification of Major Interest in Shares
09 May 2012 07:00 AM
RNS
Notification of Major Interest in Shares
09 May 2012 07:00 AM
RNS
Notification of Major Interest in Shares
08 May 2012 04:48 PM
RNS
Notification of Major Interest in Shares
03 May 2012 07:00 AM
RNS
First day of Dealings and Admission to AIM

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings